Role of T-Cells in HIV CNS Reservoir Seeding, Persistence, and Neuropathogenesis (R01 Clinical Trial Not Allowed) | RFA MH 26 110

Frequently Asked Questions (FAQs)

What is the title of this funding opportunity?

The opportunity is titled "Role of T-Cells in HIV CNS Reservoir Seeding, Persistence, and Neuropathogenesis (R01 Clinical Trial Not Allowed)."

What agency is offering this grant?

This is a National Institutes of Health (NIH) funding opportunity. The National Institute of Mental Health (NIMH) is specifically noted as part of the broader NIH AIDS effort behind the topic.

What is the funding opportunity number?

The funding opportunity number is RFA-MH-26-110.

What type of award mechanism is being used?

The mechanism is an NIH discretionary grant using the R01 mechanism.

What is the main scientific focus of this R01?

The focus is on understanding how T cells contribute to HIV establishing (seeding) and maintaining viral reservoirs in the central nervous system (CNS), and how those processes relate to ongoing neuroinflammation and neurologic complications in people living with HIV, including in the era of effective antiretroviral therapy (ART).

Why is the CNS a key area of interest in this announcement?

The announcement emphasizes that HIV enters the CNS early after infection and that persistent infection and inflammatory activity can remain detectable in CNS compartments even when ART achieves excellent viral suppression in blood and strong control in the CNS. Because neurologic complications and subtle impairments can persist despite viral control, the CNS is presented as a critical frontier for cure strategies and prevention of long-term neurological harm.

What does the opportunity mean by "CNS reservoir seeding"?

Within the context provided, CNS reservoir seeding refers to the early establishment of HIV within CNS compartments after infection, including the role immune cells (especially T cells) may play in bringing HIV into the brain and related tissues.

What does "persistence" refer to in this funding opportunity?

Persistence refers to the mechanisms that allow HIV infection and/or inflammatory activity to remain in CNS-related compartments long term despite effective ART.

What does "neuropathogenesis" mean in this context?

In this announcement, neuropathogenesis refers to pathways through which infected or activated immune cells and inflammatory dynamics in the CNS may contribute to neuronal injury, neuroinflammation, and neurologic complications in people living with HIV.

Which immune cell types are highlighted as important to HIV entry and persistence in the CNS?

The description highlights CD4 T cells and monocytes as key mediators of HIV entry into the brain and as potential ongoing sources of viral persistence and neuronal damage. It also points to recruitment of CD8 T cells into the CNS during acute infection, where they may help control viral replication but may also be linked to inflammatory dynamics relevant to neuropathogenesis.

What kinds of T-cell questions does this opportunity encourage researchers to address?

The opportunity emphasizes clarifying which T-cell populations are involved and how they behave in CNS compartments. Examples mentioned include trafficking phenotypes, tissue-resident versus infiltrating subsets, and activation or exhaustion states, as well as how these cells move into and act within CNS compartments and interact with other CNS-resident or infiltrating immune cells.

How does this opportunity relate to ART-treated populations?

The premise includes that even when ART provides excellent viral suppression in blood and strong control in the CNS, many individuals still experience HIV-associated CNS co-morbidities and subtle neurologic impairments. The opportunity therefore supports research into persistent CNS infection and inflammation under ART and how immune cells contribute to these outcomes.

Is this opportunity intended to support HIV cure research, research on co-morbidities, or both?

Both. The stated purpose aligns with two major priorities: enabling HIV cure strategies by tackling latent reservoirs (especially in hard-to-reach sites like the CNS) and understanding/mitigating HIV-associated co-morbidities that persist even in the ART era.

What does "R01 Clinical Trial Not Allowed" mean for proposed studies?

It means the supported work should be mechanistic and hypothesis-driven but not designed as a prospective clinical trial that assigns human participants to interventions to evaluate health outcomes. The project should not meet NIH's definition of a clinical trial.

What types of approaches appear to be allowed under "Clinical Trial Not Allowed," based on the description provided?

Based on the description, applicants typically interpret this as permitting a wide range of preclinical and translational approaches, including analyses of human specimens and observational clinical cohort samples, animal or ex vivo models, and advanced molecular or cellular profiling, as long as the project does not meet NIH's definition of a clinical trial.

Does this opportunity allow research that uses human samples?

Yes. The description notes analyses of human specimens and observational clinical cohort samples as examples of approaches that applicants typically interpret as allowable, provided the work is not a clinical trial.

Does this opportunity allow animal or ex vivo studies?

Yes. The description lists animal or ex vivo models as examples of approaches that applicants typically interpret as allowable, as long as the work is not a clinical trial.

What is the application due date listed in the provided information?

The original application due date provided is 2025-03-18.

Are award amounts, award ceilings, or the expected number of awards provided?

No. The provided text states that an award ceiling and expected number of awards are not specified in the source information.

What does the use of the R01 mechanism imply about project scope?

The text indicates that the R01 mechanism signals support for substantial, multi-year research projects capable of addressing complex biological questions with robust experimental plans.

What activity categories are associated with this funding instrument?

The funding instrument is described as a grant under the education and health activity categories.

What CFDA numbers are associated with this opportunity?

The opportunity lists CFDA numbers 93.242, 93.279, and 93.853.

Who is eligible to apply (in general terms)?

Eligibility is broad and includes many types of U.S. organizations and governments, nonprofit and for-profit organizations, small businesses, and a range of academic institutions. The eligibility language is designed to encourage a wide range of research institutions and organizations with relevant scientific capacity.

Are U.S. government entities eligible?

Yes. The eligibility list includes state, county, and city governments; special district governments; independent school districts; and public housing authorities or Indian housing authorities.

Are colleges and universities eligible?

Yes. Eligible applicants include public and state-controlled institutions of higher education and private institutions of higher education.

Are nonprofit organizations eligible?

Yes. The opportunity allows nonprofit organizations (both 501(c)(3) and non-501(c)(3), excluding institutions of higher education in those categories).

Are for-profit organizations eligible?

Yes. For-profit organizations (other than small businesses) are listed as eligible, and small businesses are also listed as eligible.

Are tribal governments and tribal organizations eligible?

Yes. Federally recognized Native American tribal governments are eligible, and tribal organizations that are not federally recognized are also listed as eligible.

Are faith-based or community-based organizations eligible?

Yes. Faith-based or community-based organizations are explicitly listed as eligible.

Are non-U.S. (foreign) organizations eligible to apply?

Yes. The opportunity allows non-domestic (non-U.S.) entities (foreign organizations), along with regional organizations and U.S. territories or possessions.

Are U.S. territories or possessions eligible?

Yes. U.S. territories or possessions are included in the eligibility list.

Does the announcement encourage applications from specific institution types?

Yes. It explicitly calls out additional eligible applicant groups including Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISI).

What kind of research gap is this opportunity trying to address?

It targets the gap that viral control does not necessarily mean biologic silence in the CNS. The announcement highlights that understanding immune cell behavior, trafficking, and persistence in CNS compartments is likely essential for designing strategies to reduce CNS reservoir size, limit inflammation, and protect neurological function over the long term.

What outcomes or impacts does the opportunity aim to enable, according to the description?

Based on the description, the intended impact is to improve understanding of how T cells and other immune cells contribute to CNS reservoir biology and neurologic outcomes under ART, supporting progress toward CNS-informed HIV cure strategies and mitigation of HIV-associated CNS co-morbidities.